Xbrane Biopharma Ab Stock Current Asset
| XBRANE Stock | SEK 0.19 0.01 5.56% |
Xbrane Biopharma AB fundamentals help investors to digest information that contributes to Xbrane Biopharma's financial success or failures. It also enables traders to predict the movement of Xbrane Stock. The fundamental analysis module provides a way to measure Xbrane Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Xbrane Biopharma stock.
Xbrane |
Xbrane Biopharma AB Company Current Asset Analysis
Xbrane Biopharma's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Xbrane Biopharma Current Asset | 77 M |
Most of Xbrane Biopharma's fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Xbrane Biopharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, Xbrane Biopharma AB has a Current Asset of 77 M. This is 96.42% lower than that of the Healthcare sector and 93.77% lower than that of the Drug Manufacturers - Specialty & Generic industry. The current asset for all Sweden stocks is 99.18% higher than that of the company.
Did you try this?
Run Efficient Frontier Now
Efficient FrontierPlot and analyze your portfolio and positions against risk-return landscape of the market. |
| All Next | Launch Module |
Xbrane Fundamentals
| Return On Equity | -0.37 | |||
| Return On Asset | -0.13 | |||
| Operating Margin | (4.61) % | |||
| Current Valuation | 2.32 B | |||
| Shares Outstanding | 27.51 M | |||
| Shares Owned By Insiders | 35.23 % | |||
| Shares Owned By Institutions | 22.09 % | |||
| Price To Earning | (10.92) X | |||
| Price To Book | 7.49 X | |||
| Price To Sales | 75.09 X | |||
| Revenue | 11.53 M | |||
| Gross Profit | (18.27 M) | |||
| EBITDA | (172.74 M) | |||
| Net Income | (188.38 M) | |||
| Cash And Equivalents | 44.32 M | |||
| Cash Per Share | 5.34 X | |||
| Total Debt | 36.48 M | |||
| Debt To Equity | 48.90 % | |||
| Current Ratio | 1.45 X | |||
| Book Value Per Share | 12.99 X | |||
| Cash Flow From Operations | (219.61 M) | |||
| Earnings Per Share | (7.13) X | |||
| Target Price | 136.5 | |||
| Number Of Employees | 74 | |||
| Beta | 1.37 | |||
| Market Capitalization | 2.74 B | |||
| Total Asset | 688.43 M | |||
| Retained Earnings | (29 M) | |||
| Working Capital | 64 M | |||
| Current Asset | 77 M | |||
| Current Liabilities | 13 M | |||
| Z Score | 45.0 | |||
| Net Asset | 688.43 M |
About Xbrane Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Xbrane Biopharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Xbrane Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Xbrane Biopharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Xbrane Stock
Xbrane Biopharma financial ratios help investors to determine whether Xbrane Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xbrane with respect to the benefits of owning Xbrane Biopharma security.